Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors
- 31 March 2022
- journal article
- research article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 29 (7) , 732-740
Abstract
Background: Optimal strategies for advanced hepatocellular carcinoma (HCC) tumors, such as those with vascular tumor thrombus and those with extrahepatic metastases are unclear.Methods: A literature review was conducted focusing on conversion surgery for HCC after molecular targeted therapy and therapy using immune checkpoint inhibitors.Results: Upfront surgical resection of advanced HCC tumors has been challenged at some institutions because of lack of promising therapeutic options. Preoperative transcatheter arterial chemoembolization, hepatic arterial infusion chemotherapy, and radiotherapy in patients with unresectable HCC were developed to improve long‐term outcome, but the results were not promising. Nonetheless, the recent advent of molecular targeted therapies and immune check‐point inhibitors, enabling frequent tumor responses, has accelerated the use of conversion surgery after these therapies in patients with initially unresectable HCC. Increasing numbers of conversion surgeries after lenvatinib therapy has been reported, and the first prospective clinical trial assessing conversion surgery after lenvatinib therapy in initially unresectable HCC has been commenced. Furthermore, the superiority of combination therapy using atezolizumab and bevacizumab over sorafenib, a conventional first‐line drug for unresectable HCC, in terms of overall survival and tumor response has been demonstrated, and the use of this regimen alongside conversion surgery is expected in addition to lenvatinib.Conclusion: The literature demonstrated the feasibility of conversion surgery after systemic therapy. Further clinical investigation of surgery after systemic therapy for advanced HCC may be undertaken by clearly distinguishing the tumor status as technically unresectable or oncologically unresectable but technically resectable.Keywords
Funding Information
- Japan Society for the Promotion of Science (19K09138)
This publication has 55 references indexed in Scilit:
- Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenibWorld Journal of Surgical Oncology, 2013
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resectionLiver International, 2011
- Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinomaWorld Journal of Gastroenterology, 2011
- Liver Resection after Downstaging Hepatocellular Carcinoma with SorafenibInternational Journal of Hepatology, 2011
- Neoadjuvant therapy of colorectal liver metastases: Lessons learned from clinical trialsJournal of Surgical Oncology, 2010
- Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinomaThe Korean Journal of Hepatology, 2010
- The Efficacy of Hepatic Resection after Neoadjuvant Transarterial Chemoembolization (TACE) and Radiation Therapy in Hepatocellular Carcinoma Greater Than 5 cm in SizeJournal of Korean Medical Science, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008